A compendium of next-generation patient-derived models for diverse cancers.
ElHarouni D, Al-Jazrawe M, Choi S, Dede M, Hinoue T, Misek SA, Noh H, Zanella L, Tseng YY, Francies HE, Plenker D, Kyi CW, Perez-Mayoral J, Stine MJ, Tonsing-Carter E, Agarwal R, Zenklusen JC, Clinton JM, Shelton JM, Chu TR, Hooper WF, Loinaz X, Keskula P, Tagle J, Kuhlers PC, Tercan B, Boj SF, Vasciaveo A, Tomassoni L, Crawford JM, Walsh S, Sinai C, Bhatia S, Sridevi P, Patel H, Cerone MA, , Ellrott K, Kuo CJ, Elemento O, Beyaz S, Corbo V, Spector DL, Beroukhim R, Ferguson ML, Cherniack AD, Laird PW, Robine N, McPherson A, Hoadley KA, Garnett MJ, Tuveson DA, Califano A, Spellman PT, Ligon KL, Gerhard DS, Staudt LM, Boehm JS
Vorasidenib improves response to subsequent chemoradiation in a genetically engineered mouse model of IDH-mutant glioma.
Shi DD, Calvo Fernández E, Puliyappadamba VT, Lanman TA, Xiao Y, Wen Z, Minor M, Prost D, Lasica AB, Cai F, Neumann E, Gudipelly S, Clark LM, Nguyen QD, Peña S, Wansapura J, Kaphle P, Shipman T, Levitt MM, Lin MD, Tsai AC, Lee JH, Cahill DP, Rahman R, Haas-Kogan DA, Richardson TE, Tirosh I, Jain P, Tron AE, Nakhate V, Youssef G, Dehais C, Jacob J, Reardon DA, Miller JJ, Abdullah KG, Wen PY, DeBerardinis RJ, Xu L, Touat M, Peters KB, Gonzalez Castro LN, Kaelin WG, Suvà ML, McBrayer SK
Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma.
Ghannam JY, Bryan J, Weiss J, Kovarsky D, Merrell D, Messer C, Schlueter-Kuck K, Fell GG, Lim-Fat MJ, Youssef G, Rahman R, Qin L, Young GS, Janes JT, Van Orden M, Pfaff KL, Gans A, Lin ES, Huang RY, Danysh BP, Parida L, Li S, Wen PY, Chiocca EA, Neuberg D, Ligon KL, Tirosh I, Reardon DA, Getz G, Wu CJ
Acquired genetic and cell-state changes in IDH-mutant glioma progression.
Johnson KC, Spitzer A, Varn FS, Nomura M, Garofano L, Chowdhury T, Lipsa A, Zhang L, Fernández EC, Barak T, Gulhan Ercan-Sencicek A, Peksen AB, Anderson KJ, Tesileanu CMS, Amin SB, Kocakavuk E, Zhao D, D'Angelo F, Migliozzi S, Bussema L, Gritsch S, Moon HE, Paek SH, Bielle F, Laurenge A, Di Stefano AL, Mathon B, Picca A, Sanson M, Hau AC, Hertel F, Grzyb K, Zhao Z, Wang Q, Jiang T, Miller JJ, Wakimoto H, Cahill DP, Moliterno J, Günel M, Hermes B, Sanai N, Golebiewska A, Niclou SP, Huse J, Alfred Yung WK, Lasorella A, Suvà ML, Iavarone A, Tirosh I, Verhaak RGW
Patient-friendly simplification and translation of neuroradiology impressions using artificial intelligence.
Sun W, Patil A, Vicent MA, Montagnese B, Zielke J, Hefferman GM, Pan I, Cleaver G, Eldaief MC, Patel R, Mendoza-Millan DL, Landry J, Moreno-Lizarazo O, Odukoya OA, Johnston BR, Huang KT, Arnaout O
Dose Escalation With Intensity-Modulated Proton Therapy for Patients with High-Risk Meningiomas - Results From a Phase 1 Trial.
Ehret F, Horick NK, Yeap BY, Curry WT, Nahed B, Daartz J, Johnson JM, Dagher SA, Raza SM, DeMonte F, Yeboa DN, Swanson TA, McAleer MF, Leland P, McGovern SL, Shih HA
Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.
Wen PY, Berry DA, Buxton MB, Colman H, de Groot J, Lim M, Mellinghoff I, Perry JR, Weller M, Blondin NA, Butt OH, Damek DM, de la Fuente MI, Drappatz J, Dunbar E, Giglio P, Hyddmark EV, Iwamoto F, Jaeckle KA, Kim L, Kling HM, Lee EQ, Mantica M, Mikkelsen T, Nabors B, Newton HB, Olson JJ, Schiff D, Walbert T, Weathers SP, Cloughesy T, Lassman AB,
Somatic cancer variants enriched in Alzheimer's disease microglia-like cells drive inflammatory and proliferative states.
Huang AY, Zhou Z, Talukdar M, Enyenihi L, Miller MB, Chhouk B, Rosen I, Zheng M, Zhou M, Yang A, Stronge E, Durens M, Nguyen M, Choi J, Zhao B, Khoshkhoo S, Kim J, Andersen R, An Z, Cheng Y, Ganz J, Mekerishvili L, Travaglini KJ, Gabitto MI, Hodge RD, Kaplan ES, Belk JA, Landau D, Lein ES, De Jager PL, Bennett DA, Marro SG, Papapetrou EP, Lee EA, Walsh CA
A blueprint for local and distal invasion programs in glioblastoma.
Chanoch-Myers R, Hara T, Greenwald AC, Hoefflin R, Bussema L, Weisman HR, Nieblas-Bedolla E, Gurramkonda J, Bekezhankyzy Z, Jucht A, Calvo Fernández E, Spitzer A, Fung JMH, Chiara B, Al-Holou WN, Camelo-Piragua S, Behnan J, Galli R, Wakimoto H, Suvà ML, Tirosh I
Multidimensional profiling of heterogeneity in supratentorial ependymomas.
Jeong D, Danielli SG, Maaß KK, Ghasemi DR, Tetzlaff SK, Reyhan E, Jiang L, Katiyar S, Sundheimer JK, Lo Cascio C, Neyazi S, de Biagi-Junior CAO, Couvillon E, Castellani S, Pazyra-Murphy M, Mullally M, Dehler MP, Englinger B, Nascimento A, Cruzeiro GAV, Marques JG, Haase RD, Nguyen CM, Baumgartner AC, Rozowsky JS, Hack OA, Shaw ML, Lotsch-Gojo D, Bruckner K, Korshunov A, Pfister SM, Kool M, Nowakowski TJ, Gojo J, Baird L, Alexandrescu S, Pajtler KW, Venkataramani V, Filbin MG
NKG2D upregulation sensitizes tumors to combined anti-PD1 and anti-VEGF therapy and prevents hearing loss.
Lu S, Yin Z, Wu L, Sun Y, Chen J, Wu LMN, Oblinger JL, Blake DC, Xiu B, Landegger LD, Seist R, Ho W, Jones AP, Muzikansky A, Stankovic KM, Plotkin SR, Chang LS, Xu L
Cognitive Function, Quality of Life, and Survival Outcomes in Patients with Lower Grade Gliomas Treated with Proton Radiation Therapy: A Phase II study.
Slater JM, Horick NK, Nachtigall LB, Parsons MW, Tritos NA, Faje AT, Dietrich J, Fullerton B, Sherman JC, Curry WT, Arrillaga-Romany IC, Cahill DP, Nahed BV, Wang IS, Botticello TM, Oh KS, Yeap BY, Shih HA
